LPX Lipoxen

RNS Number:6854N
Lipoxen PLC
11 February 2008

                                  Lipoxen PLC

                          ("Lipoxen" or "the Company")



                               Change of Adviser



London, UK, 11 February 2008 - Lipoxen PLC (AIM: LPX) a bio-pharmaceutical
company specialising in the development of high value differentiated
biologicals, vaccines and oncology drugs, today announces the appointment of
Landsbanki Securities (UK) Limited as Nominated Adviser and Broker to the
company with immediate effect.



                                      Ends



Enquiries:


Lipoxen plc                                                       +44 (0)20 7691 3583
M. Scott Maguire, Chief Executive Officer
Colin Hill, Finance Director

Landsbanki Securities (UK) Limited                                +44 (0)20 7426 9000
Shaun Dobson
Claes Spang

Citigate Dewe Rogerson                                            +44 (0)20 7638 9571
David Dible
Emma Palmer





Notes to Editors



Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the
development of high value differentiated biologicals, vaccines and oncology
drugs. Products currently under development include improved formulations of
important biologicals such as EPO, G-CSF, insulin and Interferon-alpha. These
novel products which are based on Lipoxen's proprietary PolyXen(R) technology
address markets in excess of US$1 billion. This technology is designed to
improve the stability, biological half-life and immunologic characteristics of
therapeutic proteins naturally. Lipoxen has two further naturally-derived
proprietary delivery technologies, ImuXen(R) and a related liposomal technology
for the formulation of cytotoxic oncology drugs, which are being developed to
enhance the efficacy and safety of various vaccines such as a multivalent
Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer
agents like paclitaxel. The Company's proprietary delivery technologies are
attracting significant interest and Lipoxen is currently co-developing products
with the Serum Institute of India Limited (one of the world's leading vaccine
companies, India's largest biotech company and a major shareholder in Lipoxen)
and has license agreements in place with Baxter International and InterVet, a
leading animal health company.



Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange
in January 2006.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

APPUUUPWPUPRGUB

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024